Casgevy's approval is significant for gene editing, but fisc...
Casgevy's approval is significant for gene editing, but fiscal barriers to commercialization, especially in Europe, could be difficult. Past experiences, like bluebird bio's gene therapy drug withdrawal due to pricing goals failure, indicate potential challenges.
U.K. Approves First 'Genetic Scissors' Treatment -- Barrons.com
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment